Citations (21)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (4)
Juan Macías, Karin Neukam, Josep Mallolas, Luis F. López-Cortés, José A. Cartón, Pere Domingo, Santiago Moreno, José A. Iribarren, Bonaventura Clotet, Manell Crespo, Ignacio de Los Santos, Enrique Ortega, Hernando Knobel, María J. Jiménez-Expósito & Juan A. Pineda. (2012) Liver Toxicity of Initial Antiretroviral Drug Regimens Including Two Nucleoside Analogs Plus One Non-Nucleoside Analog or One Ritonavir-Boosted Protease Inhibitor in HIV/HCV-Coinfected Patients. HIV Clinical Trials 13:2, pages 61-69.
Read now
Read now
José L. Casado, María Del Palacio, Javier Moya, José M. Rodriguez, Ana Moreno, María J. Perez-Elías, Ana Belso, Fernando Dronda & Santiago Moreno. (2011) Safety and Pharmacokinetics of Lopinavir in HIV/HCV Coinfected Patients with Advanced Liver Disease. HIV Clinical Trials 12:5, pages 235-243.
Read now
Read now
Antonio Rivero & Inés Pérez-Camacho. (2010) Does lopinavir/ritonavir alter the primary gingival epithelium?. Expert Review of Anti-infective Therapy 8:12, pages 1345-1349.
Read now
Read now
Ashish Chandwani & Jonathan Shuter. (2008) Lopinavir/ritonavir in the treatment of HIV-1 infection: a review. Therapeutics and Clinical Risk Management 4:5, pages 1023-1033.
Read now
Read now
Articles from other publishers (17)
Dongsub Jeon, Minkook Son & Jonggi Choi. (2021) Impact of liver cirrhosis on the clinical outcomes of patients with COVID-19: a nationwide cohort study of Korea. The Korean Journal of Internal Medicine 36:5, pages 1092-1101.
Crossref
Crossref
Clementine LevyGuillaume LassaillyErika ParmentierThibault DuburcqPhilippe MathurinJulien Poissy. (2020) Caution With the Use of Lopinavir/Ritonavir in Severely Ill Patients for the Treatment of SARS-CoV-2: A Report of Severe Jaundice. American Journal of Gastroenterology 115:10, pages 1716-1718.
Crossref
Crossref
Sophie L. Penman, Robyn T. Kiy, Rebecca L. Jensen, Christopher Beoku‐Betts, Ana Alfirevic, David Back, Saye H. Khoo, Andrew Owen, Munir Pirmohamed, B. Kevin Park, Xiaoli Meng, Christopher E. Goldring & Amy E. Chadwick. (2020) Safety perspectives on presently considered drugs for the treatment of COVID‐19. British Journal of Pharmacology 177:19, pages 4353-4374.
Crossref
Crossref
Grace Lai-Hung Wong, Vincent Wai-Sun Wong, Alex Thompson, Jidong Jia, Jinlin Hou, Cosmas Rinaldi Adithya Lesmana, Adityo Susilo, Yasuhito Tanaka, Wah-Kheong Chan, Ed Gane, Arlinking K Ong-Go, Seng-Gee Lim, Sang Hoon Ahn, Ming-Lung Yu, Teerha Piratvisuth & Henry Lik-Yuen Chan. (2020) Management of patients with liver derangement during the COVID-19 pandemic: an Asia-Pacific position statement. The Lancet Gastroenterology & Hepatology 5:8, pages 776-787.
Crossref
Crossref
Fengxiang Qin, Junjun Jiang, Chunwei Qin, Yunxuan Huang, Bingyu Liang, Yuexiang Xu, Jiegang Huang, Zhiliang Xu, Chuanyi Ning, Yanyan Liao, Ning Zang, Jingzhen Lai, Wudi Wei, Jun Yu, Li Ye, Xionglin Qin & Hao Liang. (2019) Liver damage in patients living with HIV on antiretroviral treatment with normal baseline liver function and without HBV/HCV infection: an 11-year retrospective cohort study in Guangxi, China. BMJ Open 9:4, pages e023140.
Crossref
Crossref
Karin Neukam, José A. Mira, Antonio Collado, Antonio Rivero-Juárez, Patricia Monje-Agudo, Josefa Ruiz-Morales, María José Ríos, Dolores Merino, Francisco Téllez, Inés Pérez-Camacho, María Carmen Gálvez-Contreras, Antonio Rivero & Juan A. Pineda. (2016) Liver Toxicity of Current Antiretroviral Regimens in HIV-Infected Patients with Chronic Viral Hepatitis in a Real-Life Setting: The HEPAVIR SEG-HEP Cohort. PLOS ONE 11:2, pages e0148104.
Crossref
Crossref
. (2013) Documento de consenso de GeSIDA/Plan Nacional sobre el Sida respecto al tratamiento antirretroviral en adultos infectados por el virus de la inmunodeficiencia humana (actualización enero 2013). Enfermedades Infecciosas y Microbiología Clínica 31:9, pages 602.e1-602.e98.
Crossref
Crossref
Elena López Aspiroz, Salvador Enrique Cabrera Figueroa, Alfonso Domínguez-Gil Hurlé & María José García Sánchez. (2013) Nuevas estrategias en la optimización posológica de lopinavir/ritonavir en pacientes infectados por el virus de la inmunodeficiencia humana. Enfermedades Infecciosas y Microbiología Clínica 31:1, pages 36-43.
Crossref
Crossref
. (2012) Documento de consenso de Gesida/Plan Nacional sobre el Sida respecto al tratamiento antirretroviral en adultos infectados por el virus de la inmunodeficiencia humana (actualización enero de 2012). Enfermedades Infecciosas y Microbiología Clínica 30:6, pages e1-e89.
Crossref
Crossref
Feng Li, Jie Lu & Xiaochao Ma. (2012) CPY3A4-Mediated Lopinavir Bioactivation and Its Inhibition by Ritonavir. Drug Metabolism and Disposition 40:1, pages 18-24.
Crossref
Crossref
Nicolás MerchanteLuis F. López-CortésMarcial Delgado-FernándezMaria J. Ríos-VillegasManuel Márquez-SoleroDolores MerinoJuan PasquauCarolina García-FiguerasMaria Angeles Martínez-PérezMohamed OmarAntonio RiveroJuan MacíasRosario MataJuan Antonio Pineda, on behalf of the Grupo Anda. (2011) Liver Toxicity of Antiretroviral Combinations Including Fosamprenavir Plus Ritonavir 1400/100 mg Once Daily in HIV/Hepatitis C Virus-Coinfected Patients. AIDS Patient Care and STDs 25:7, pages 395-402.
Crossref
Crossref
Mario Ferreira Peixoto, José Henrique Pilotto, Sonia Karolina Stoszek, Regis Kreitchmann, Marisa Márcia Mussi-Pinhata, Victor Hugo Melo, Esaú Custodio João, Mariana Ceriotto, Ricardo da Silva de Souza & Jennifer Read. (2011) Lopinavir/ritonavir dosing during pregnancy in Brazil and maternal/infant laboratory abnormalities. The Brazilian Journal of Infectious Diseases 15:3, pages 253-261.
Crossref
Crossref
Jia-Jia Chen, Cheng-Bo Yu, Wei-Bo Du & Lan-Juan Li. (2011) Prevalence of hepatitis B and C in HIV-infected patients: a meta-analysis. Hepatobiliary & Pancreatic Diseases International 10:2, pages 122-127.
Crossref
Crossref
F Ortu, LE Weimer, M Floridia & PE Manconi. (2010) Raltegravir, tenofovir, and emtricitabine in an HIV-Infected patient with HCV chronic hepatitis, NNRTI intolerance and protease inhibitors-induced severe liver toxicity. European Journal of Medical Research 15:2.
Crossref
Crossref
John Hornberger, Kit Simpson, Ashwini Shewade, Birgitta Dietz, Robert Baran & Thomas Podsadecki. (2010) Broadening the perspective when assessing evidence on boosted protease inhibitor-based regimens for initial antiretroviral therapy. Advances in Therapy 27:11, pages 763-773.
Crossref
Crossref
Panel de expertos de Gesida & Plan Nacional sobre el Sida. (2010) Documento de consenso del Grupo de Estudio de Sida/Plan Nacional sobre el Sida respecto al tratamiento antirretroviral en adultos infectados por el virus de la inmunodeficiencia humana (actualización enero 2010). Enfermedades Infecciosas y Microbiología Clínica 28:6, pages 362.e1-362.e91.
Crossref
Crossref
J. Macias, F. Orihuela, A. Rivero, P. Viciana, M. Marquez, J. Portilla, M. J. Rios, L. Munoz, J. Pasquau, M. A. Castano, L. Abdel-Kader & J. A. Pineda. (2008) Hepatic safety of tipranavir plus ritonavir (TPV/r)-based antiretroviral combinations: effect of hepatitis virus co-infection and pre-existing fibrosis. Journal of Antimicrobial Chemotherapy 63:1, pages 178-183.
Crossref
Crossref